PACB Stock Overview

The latest trading day saw Pacific Biosciences of California (PACB) settling at $1.44, representing a -1.37% change from its previous close.

PacBio to leverage Chris' extensive expertise in diagnostics and laboratory testing markets, as Board Member David Meline steps down. PacBio to leverage Chris' extensive expertise in diagnostics and laboratory testing markets, as Board Member David Meline steps down.

PacBio announces positive study results for HiFi long-read sequencing technology in identifying genetic causes of rare diseases.

PacBio reports dismal preliminary fourth-quarter 2024 results, caused by lower instrument. New launches and clinical focus set the stage for market growth in 2025.

Commenced shipment of the Vega ™ benchtop system ahead of schedule, bringing HiFi sequencing to more customers

PACB and Intus Bio collaborate to launch GutID, the first commercial human gut health test.

PacBio delivers the first Vega systems to Berry Genomics to develop and optimize its targeted assays to support screening programs in China and other markets.

MENLO PARK, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, and Intus Bio, a leader in microbiome research and discovery, today unveiled GutID, the first commercial human gut health test powered by Intus Bio's groundbreaking Titan-1 platform and PacBio's HiFi sequencing technology. By combining Intus Bio's patented strain-level resolution assay and AI-powered analysis with PacBio's renowned sequencing accuracy, GutID sets a new benchmark in gut microbiome testing, and is the only comprehensive and accurate gut microbiome test available today.

Pacific Biosciences of California (PACB) closed at $2 in the latest trading session, marking a +0.5% move from the prior day.